Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon contact icon menu icon
Medicilon Logo
|
search icon close search icon contact icon menu icon
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Jul 16,2021
[Medicilon Assist] QHRD110 Capsules, a Class 1 Anti-cancer Drug Targeted by Qianhong, was Approved for Clinical Trials
Recently, Changzhou Qianhong Bio-Pharma targeted anti-cancer Class 1 new drug QHRD110 capsules was approved for clinical trials.
More
[Medicilon Assist] QHRD110 Capsules, a Class 1 Anti-cancer Drug Targeted by Qianhong, was Approved for Clinical Trials
Jul 06,2021
Medicilon Helps Hangzhou Dac Biotechnology Muc1-ADC Get Clinical Approval
Recently, a recombinant humanized anti-MUC1 monoclonal antibody-Tub201 coupling agent (hereinafter referred to as "Muc1") for the treatment of advanced solid tumor class 1 ADC drug injection from Dac Biotechnology was approved for clinical use. This is the first clinically approved Muc1-ADC drug in China.
More
Medicilon Helps Hangzhou Dac Biotechnology Muc1-ADC Get Clinical Approval
Jun 30,2021
[Medicilon Assist]KBMAB-16 for the Treatment of Sarcoidosis has been Approved by the FDA for Clinical Trials
Recently, the orphan drug KBMAB-16 (intravenous injection of tumor necrosis factor-α inhibitor), a major project of a well-known Chinese pharmaceutical company located in Chengdu, was successfully approved for clinical trial application (IND) by the US Food and Drug Administration (US FDA).
More
[Medicilon Assist]KBMAB-16 for the Treatment of Sarcoidosis has been Approved by the FDA for Clinical Trials
Jun 25,2021
Medicilon's "New Drugs + AI Innov Forum" was successful held
When AI accurately predicts the "difficult” protein 3D structure; When AI completes the new drug design within 21 days; When AI discovers a new mechanism
More
Medicilon's "New Drugs + AI Innov Forum" was successful held
Jun 08,2021
Medicilon assists Palaatu to obtain clinical approval for Class 1 new drug PA9159 for rhinitis
On June 2, 2021, the National Medical Products Administration (NMPA) officially announced that the glucocorticoid drug PA9159 nasal spray was approved for clinical use.
More
Medicilon assists Palaatu to obtain clinical approval for Class 1 new drug PA9159 for rhinitis
May 14,2021
Safety assessment lab of process chemistry
Safety assessment lab of process chemistry In the research and development process of innovative drugs, the chemical process research of drugs plays a pivotal role. 
More
Safety assessment lab of process chemistry
May 01,2021
Vastpro and Medicilon signed a strategic cooperation agreement for pre-clinical IND application services
On July 15, 2021, Vastpro and Medicilon signed a strategic cooperation agreement in the Medicilon Chuansha Park to reach a long-term strategic cooperation relationship.Vastpro president
More
Vastpro and Medicilon signed a strategic cooperation agreement for pre-clinical IND application services
Apr 25,2021
Medicilon Appoints Two Vice Presidents
Shanghai Medicilon Inc. recently assigned Dr. Haifeng Yin as the vice president of process chemistry and formulation study, Dr. Baohong Cao as the vice president
More
Medicilon Appoints Two Vice Presidents
Apr 21,2021
Medicilon assists HitGen's HG381 to be approved as China's first clinical STING agonist
On April 8, 2021, the clinical trial application of HG381 for injection, developed by HitGen, was approved by National Medical Products Administration (NMPA).  HG381 for
More
Medicilon assists HitGen's HG381 to be approved as China's first clinical STING agonist
Apr 08,2021
Medicilon will participate 2021 AACR Virtual Annual Meeting
#Medicilon will exhibit the 2021 AACR Virtual Annual Meeting from April 10-15.  Please visit our virtual booth for more information on our oncology and preclinical
More
Medicilon will participate 2021 AACR Virtual Annual Meeting
Mar 29,2021
Medicilon assists Livzon Pharmaceuticals Group to obtain the clinical approval of novel coronavirus vaccine V-01
Livzon Pharmaceutical Group Inc. (Livzon) obtained a "novel coronavirus recombinant protein vaccine” (V-01) clinical trial approval from the National Medical Products Administration (NMPA) (Batch No.
More
Medicilon assists Livzon Pharmaceuticals Group to obtain the clinical approval of novel coronavirus vaccine V-01
Mar 08,2021
Medicilon will participate 2021 SOT Virtual Annual Meeting
Medicilon will exhibit the 2021 SOT Virtual Annual Meeting from March 12-26.  Please visit our virtual booth to meet our VPs, Dr. Frank Wang, Dr.
More
Medicilon will participate 2021 SOT Virtual Annual Meeting